-
1 Comment
NATCO Pharma Limited is currently in a long term uptrend where the price is trading 14.5% above its 200 day moving average.
From a valuation standpoint, the stock is 48.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.1.
NATCO Pharma Limited's total revenue sank by 26.3% to $4B since the same quarter in the previous year.
Its net income has dropped by 40.0% to $627M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.9% to $2B since the same quarter in the previous year.
Based on the above factors, NATCO Pharma Limited gets an overall score of 2/5.
Exchange | NSE |
---|---|
ISIN | INE987B01026 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
CurrencyCode | INR |
PE Ratio | 7.95 |
---|---|
Target Price | 1047 |
Market Cap | 148B |
Dividend Yield | 0.8% |
Beta | 0.34 |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NATCOPHARM.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025